Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD). Specifically, it is intended to treat LPLD in patients with severe or multiple pancreatitis attacks, despite dietary fat restrictions. TV-45070 is a small-molecule inhibitor of the sodium channel Nav1.7 and other sodium channels, including those that are expressed in the pain-sensing peripheral nervous system. XEN901 is developed for the treatment of rare infantile epileptic encephalopathy and other forms of epilepsy. XEN1101, is a potassium channel modulator for the treatment of epilepsy. Its Extreme Genetics discovery platform enables the Company to identify drug targets that are more biologically relevant in humans.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:XENE
- CUSIP: N/A
- Web: www.xenon-pharma.com
Capitalization:- Market Cap: $52.19 million
- Outstanding Shares: 17,998,000
Average Prices:- 50 Day Moving Avg: $3.02
- 200 Day Moving Avg: $4.07
- 52 Week Range: $2.25 - $9.95
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -1.88
- P/E Growth: -0.06
Sales & Book Value:- Annual Revenue: $819,999.00
- Price / Sales: 63.65
- Book Value: $2.80 per share
- Price / Book: 1.04
Profitability:- EBIDTA: ($28,010,000.00)
- Net Margins: -3,489.63%
- Return on Equity: -47.53%
- Return on Assets: -44.74%
Debt:- Current Ratio: 13.96%
- Quick Ratio: 13.96%
Misc:- Average Volume: 65,325 shs.
- Beta: 1.45
- Short Ratio: 3.97
Frequently Asked Questions for Xenon Pharmaceuticals (NASDAQ:XENE)
What is Xenon Pharmaceuticals' stock symbol?
Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."
How were Xenon Pharmaceuticals' earnings last quarter?
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) issued its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.03. The firm earned $0.02 million during the quarter, compared to analyst estimates of $0.38 million. Xenon Pharmaceuticals had a negative net margin of 3,489.63% and a negative return on equity of 47.53%. View Xenon Pharmaceuticals' Earnings History.
When will Xenon Pharmaceuticals make its next earnings announcement?
Where is Xenon Pharmaceuticals' stock going? Where will Xenon Pharmaceuticals' stock price be in 2017?
5 brokers have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $5.00 to $20.00. On average, they expect Xenon Pharmaceuticals' share price to reach $12.50 in the next year. View Analyst Ratings for Xenon Pharmaceuticals.
What are analysts saying about Xenon Pharmaceuticals stock?
Here are some recent quotes from research analysts about Xenon Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada. " (7/1/2017)
- 2. Jefferies Group LLC analysts commented, "Several key ph.II readouts, XEN801 in acne (March) and TV-45070 in post-herpetic neuralgia (PHN) (mid-year), should provide sig. NT stock catalysts. Based on our analyses, our view is their acne and pain programs collectively could generate $1.5B cumulative future royalties/milestones if successful, and a valuation we believe overly discounts the promise of their pipeline and platform, we view reward/risk favorably. Assuming at Buy with $13 PT." (3/13/2017)
Who are some of Xenon Pharmaceuticals' key competitors?
Some companies that are related to Xenon Pharmaceuticals include Otonomy (OTIC), Ophthotech Corporation (OPHT), MEI Pharma (MEIP), Affimed N.V. (AFMD), Dicerna Pharmaceuticals (DRNA), Zafgen (ZFGN), ADMA Biologics (ADMA), Lipocine (LPCN), ProNAi Therapeutics (SRRA), Aeglea BioTherapeutics (AGLE), Pfenex (PFNX), Ergomed PLC (ERGO), Rexahn Pharmaceuticals (RNN), Applied Genetic Technologies Corporation (AGTC), Akari Therapeutics PLC (AKTX), ImmuPharma PLC (IMM), Motif Bio PLC (MTFB) and TRACON Pharmaceuticals (TCON).
Who are Xenon Pharmaceuticals' key executives?
Xenon Pharmaceuticals' management team includes the folowing people:
- Michael M. Tarnow, Chairman of the Board
- Ian C. Mortimer MBA., CPA., CMA., Chief Financial Officer, Chief Operating Officer
- James R. Empfield, Senior Vice President - Drug Discovery
- Robin Paul Sherrington Ph.D., Senior Vice President of Business and Corporate Development
- Charles M. Cohen Ph.D., Vice President - Biology
- Yigal Paul Goldberg M.B., ChB., Ph.D., Vice President of Clinical Development
- Karen G. Corraini J.D., General Counsel and Corporate Secretary
- Simon Neil Pimstone M.B., ChB., Ph.D., President, Chief Executive Officer, Director
- Mohammad Azab, Director
- Steven R. Gannon, Director
Who owns Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Capital World Investors (7.94%), DAFNA Capital Management LLC (2.10%), Tekla Capital Management LLC (1.94%), Sphera Funds Management LTD. (1.27%), K2 Principal Fund L.P. (0.91%) and Artal Group S.A. (0.83%). Company insiders that own Xenon Pharmaceuticals stock include Bvf Partners L P/Il, Frank A Holler, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon, Value Fund L P Biotechnology and Y Paul Goldberg. View Institutional Ownership Trends for Xenon Pharmaceuticals.
Who sold Xenon Pharmaceuticals stock? Who is selling Xenon Pharmaceuticals stock?
Who bought Xenon Pharmaceuticals stock? Who is buying Xenon Pharmaceuticals stock?
Xenon Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including K2 Principal Fund L.P., DAFNA Capital Management LLC and Scotia Capital Inc.. Company insiders that have bought Xenon Pharmaceuticals stock in the last two years include Bvf Partners L P/Il, Gary Patou, Ian Mortimer, James R Empfield, Michael R Hayden, Mohammad Azab, Raymond Winquist, Richard H Scheller, Simon N Pimstone, Steven Gannon and Value Fund L P Biotechnology. View Insider Buying and Selling for Xenon Pharmaceuticals.
How do I buy Xenon Pharmaceuticals stock?
Shares of Xenon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xenon Pharmaceuticals' stock price today?
One share of Xenon Pharmaceuticals stock can currently be purchased for approximately $2.90.
MarketBeat Community Rating for Xenon Pharmaceuticals (NASDAQ XENE)MarketBeat's community ratings are surveys of what our community members think about Xenon Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Xenon Pharmaceuticals (NASDAQ:XENE)Earnings History by Quarter for Xenon Pharmaceuticals (NASDAQ XENE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/1/2017 | | ($0.08) | | | | | N/A |  |
| 8/3/2017 | 6/30/2017 | ($0.38) | ($0.41) | $0.38 million | $0.02 million | View | Listen | |
| 3/8/2017 | 12/31/2016 | ($0.42) | ($0.32) | $0.40 million | $0.38 million | View | Listen | |
| 11/3/2016 | Q316 | ($0.43) | ($0.51) | $0.40 million | $0.41 million | View | Listen | |
| 8/3/2016 | Q216 | ($0.48) | ($0.42) | $0.50 million | $0.41 million | View | N/A | |
| 5/10/2016 | Q116 | ($0.21) | ($0.23) | $3.30 million | $0.60 million | View | Listen | |
| 3/8/2016 | Q415 | ($0.16) | ($0.27) | $4.90 million | $3.23 million | View | Listen | |
| 11/10/2015 | Q315 | ($0.02) | ($0.27) | $4.65 million | $4.29 million | View | Listen | |
| 8/10/2015 | Q215 | ($0.16) | ($0.07) | $4.90 million | $4.05 million | View | Listen | |
| 5/12/2015 | Q115 | $0.14 | ($0.30) | $4.65 million | $4.00 million | View | Listen | |
| 3/12/2015 | Q4 | ($0.09) | $1.57 | $5.10 million | $4.43 million | View | Listen | |
| 12/15/2014 | | $0.41 | $1.69 | $5.00 million | $13.19 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Xenon Pharmaceuticals (NASDAQ:XENE)2017 EPS Consensus Estimate: ($0.66)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q2 2017 | 1 | ($0.35) | ($0.35) | ($0.35) |
| Q3 2017 | 1 | ($0.29) | ($0.29) | ($0.29) |
| Q4 2017 | 1 | $0.32 | $0.32 | $0.32 |
(Data provided by Zacks Investment Research)
Dividend History for Xenon Pharmaceuticals (NASDAQ:XENE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Xenon Pharmaceuticals (NASDAQ:XENE)Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 55.30%
Insider Trades by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/18/2017 | Mohammad Azab | Director | Buy | 6,335 | $2.90 | $18,371.50 | |
| 8/18/2017 | Raymond Winquist | Insider | Buy | 1,000 | $3.00 | $3,000.00 | |
| 8/15/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 18,858 | $2.41 | $45,447.78 | |
| 8/15/2017 | James R Empfield | SVP | Buy | 10,000 | $2.48 | $24,800.00 | |
| 8/15/2017 | Value Fund L P Biotechnology | Insider | Buy | 60,202 | $2.61 | $157,127.22 | |
| 8/14/2017 | Bvf Partners L P/Il | Major Shareholder | Buy | 41,344 | $2.70 | $111,628.80 | |
| 8/14/2017 | Michael R Hayden | Director | Buy | 15,000 | $2.75 | $41,250.00 | |
| 8/11/2017 | Steven Gannon | Director | Buy | 15,000 | $2.82 | $42,300.00 | |
| 8/10/2017 | Ian Mortimer | CFO | Buy | 15,000 | $2.88 | $43,200.00 | |
| 8/10/2017 | Richard H Scheller | Director | Buy | 7,000 | $2.85 | $19,950.00 | |
| 8/10/2017 | Simon N Pimstone | CEO | Buy | 6,000 | $2.90 | $17,400.00 | |
| 8/8/2017 | Gary Patou | Director | Buy | 5,000 | $3.00 | $15,000.00 | |
| 6/27/2017 | Value Fund L P Biotechnology | Insider | Buy | 85,461 | $4.00 | $341,844.00 | |
| 6/22/2017 | Value Fund L P Biotechnology | Insider | Buy | 20,411 | $4.00 | $81,644.00 | |
| 6/19/2017 | Value Fund L P Biotechnology | Insider | Buy | 26,408 | $3.84 | $101,406.72 | |
| 6/7/2017 | Value Fund L P Biotechnology | Insider | Buy | 358,698 | $3.81 | $1,366,639.38 | |
| 12/15/2016 | Frank A Holler | Director | Sell | 30,000 | $7.85 | $235,500.00 | |
| 8/19/2016 | Frank A Holler | Director | Sell | 11,938 | $7.65 | $91,325.70 | |
| 8/18/2016 | Frank A Holler | Director | Sell | 18,062 | $7.93 | $143,231.66 | |
| 6/24/2016 | Ian Mortimer | CFO | Buy | 5,300 | $6.22 | $32,966.00 | |
| 9/24/2015 | Y. Paul Goldberg | VP | Sell | 22,149 | $8.88 | $196,683.12 | |
(Data available from 1/1/2013 forward)
Headline Trends for Xenon Pharmaceuticals (NASDAQ:XENE)
Latest Headlines for Xenon Pharmaceuticals (NASDAQ:XENE)
| Source: |
|
| Date | Headline |
|---|
 | -$0.08 EPS Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter
www.americanbankingnews.com - September 12 at 8:26 AM |
| Xenon Pharmaceuticals Inc. (XENE) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - August 29 at 9:06 AM |
| $6.52 Million in Sales Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter
www.americanbankingnews.com - August 26 at 1:30 AM |
 | Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 25 at 12:52 PM |
| Mohammad Azab Purchases 6,335 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - August 21 at 8:32 PM |
| James R. Empfield Acquires 10,000 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - August 17 at 8:52 PM |
 | Gainers & Losers Of Aug.16: XENE, JNCE, MYOK, ADMS, LIFE...
www.finanznachrichten.de - August 17 at 9:33 AM |
| Xenon Pharmaceuticals Inc. (XENE) Major Shareholder Purchases $45,447.78 in Stock
www.americanbankingnews.com - August 16 at 9:36 PM |
| Xenon Pharmaceuticals Inc. (XENE) Major Shareholder Buys $111,628.80 in Stock
www.americanbankingnews.com - August 16 at 9:14 PM |
| Xenon Pharmaceuticals Inc. (XENE) Insider Buys $157,127.22 in Stock
www.americanbankingnews.com - August 16 at 8:46 PM |
| Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 15 at 9:08 PM |
| Insider Buying: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Buys 7,000 Shares of Stock
www.americanbankingnews.com - August 15 at 12:16 AM |
| Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CEO Purchases $17,400.00 in Stock
www.americanbankingnews.com - August 15 at 12:16 AM |
| Michael R. Hayden Acquires 15,000 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Stock
www.americanbankingnews.com - August 14 at 11:46 PM |
| Insider Buying: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Buys 15,000 Shares of Stock
www.americanbankingnews.com - August 14 at 11:46 PM |
| Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Acquires $43,200.00 in Stock
www.americanbankingnews.com - August 14 at 11:46 PM |
| Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gary Patou Buys 5,000 Shares
www.americanbankingnews.com - August 10 at 10:42 PM |
| Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Expected to Post Quarterly Sales of $6.63 Million
www.americanbankingnews.com - August 8 at 7:46 AM |
| $0.01 EPS Expected for Xenon Pharmaceuticals Inc. (XENE) This Quarter
www.americanbankingnews.com - August 6 at 12:28 PM |
| Xenon Pharmaceuticals Inc. (NASDAQ:XENE) PT Set at $5.00 by Jefferies Group LLC
www.americanbankingnews.com - August 5 at 9:36 AM |
| Xenon Pharmaceuticals Inc. (XENE) Releases Earnings Results
www.americanbankingnews.com - August 4 at 3:52 PM |
| Xenon Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - August 4 at 10:10 AM |
| Xenon Pharmaceuticals Inc. (XENE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - August 4 at 8:52 AM |
| Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - July 28 at 10:07 AM |
| Xenon Pharmaceuticals Inc. (XENE) to Release Earnings on Tuesday
www.americanbankingnews.com - July 25 at 7:32 AM |
| Xenon Pharmaceuticals Inc. (XENE) Expected to Announce Quarterly Sales of $380,000.00
www.americanbankingnews.com - July 19 at 3:02 PM |
| Zacks: Analysts Anticipate Xenon Pharmaceuticals Inc. (XENE) to Post -$0.38 Earnings Per Share
www.americanbankingnews.com - July 17 at 11:29 AM |
| Xenon Pharmaceuticals Inc. (XENE) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:57 AM |
| Xenon Pharmaceuticals Inc. (XENE) PT Lowered to $5.00
www.americanbankingnews.com - July 2 at 2:34 PM |
| Xenon Pharmaceuticals Inc. (XENE) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - July 1 at 9:28 AM |
| Xenon Pharmaceuticals Inc. (XENE) to Post Q3 2017 Earnings of ($0.29) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - June 30 at 8:06 AM |
| Value Fund L. P. Biotechnology Purchases 85,461 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - June 29 at 7:47 PM |
| Jefferies Group Weighs in on Xenon Pharmaceuticals Inc.'s Q4 2017 Earnings (XENE)
www.americanbankingnews.com - June 29 at 9:54 AM |
| Teva/Xenon Nerve Pain Candidate Fails in Phase II Study
finance.yahoo.com - June 29 at 8:07 AM |
| Xenon Pharmaceuticals to Host Conference Call and Webcast Today at 9:00 a.m. Eastern Time to Discuss Topline Results from TV-45070 Phase 2b Clinical Trial in PHN
finance.yahoo.com - June 28 at 3:32 AM |
| Insider Buying: Xenon Pharmaceuticals Inc. (XENE) Insider Acquires 20,411 Shares of Stock
www.americanbankingnews.com - June 23 at 10:34 PM |
| Xenon Pharmaceuticals Inc. (XENE) Expected to Post Quarterly Sales of $450,000.00
www.americanbankingnews.com - June 23 at 5:52 PM |
| Brokerages Anticipate Xenon Pharmaceuticals Inc. (XENE) to Announce -$0.38 EPS
www.americanbankingnews.com - June 21 at 7:34 AM |
| Value Fund L. P. Biotechnology Purchases 26,408 Shares of Xenon Pharmaceuticals Inc. (XENE) Stock
www.americanbankingnews.com - June 20 at 10:20 AM |
| Xenon Pharmaceuticals Inc. (XENE) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - June 13 at 7:45 AM |
| Jefferies Group LLC Reiterates "Buy" Rating for Xenon Pharmaceuticals Inc. (XENE)
www.americanbankingnews.com - June 12 at 8:28 AM |
| Insider Buying: Xenon Pharmaceuticals Inc (XENE) Insider Acquires 358,698 Shares of Stock
www.americanbankingnews.com - June 8 at 7:12 PM |
| Xenon Pharmaceuticals, Inc. :XENE-US: Earnings Analysis: Q1, 2017 By the Numbers : June 2, 2017
finance.yahoo.com - June 3 at 2:34 AM |
| Xenon Pharmaceuticals to Present at the Jefferies 2017 Healthcare Conference
finance.yahoo.com - June 3 at 2:34 AM |
| $450,000.00 in Sales Expected for Xenon Pharmaceuticals Inc (XENE) This Quarter
www.americanbankingnews.com - May 28 at 10:46 AM |
| Zacks: Brokerages Expect Xenon Pharmaceuticals Inc (XENE) Will Post Earnings of -$0.38 Per Share
www.americanbankingnews.com - May 26 at 10:11 AM |
| Xenon Pharmaceuticals Inc (XENE) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 19 at 7:50 AM |
| Xenon Pharmaceuticals Inc (XENE) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - May 16 at 3:58 PM |
| Analysts Set Expectations for Xenon Pharmaceuticals Inc's FY2017 Earnings (XENE)
www.americanbankingnews.com - May 12 at 11:44 AM |
| Xenon Pharmaceuticals Inc (XENE) Given "Buy" Rating at Jefferies Group LLC
www.americanbankingnews.com - May 11 at 4:46 PM |
Xenon Pharmaceuticals (XENE) Chart for Thursday, September, 21, 2017
